Cases and Conversations: Integrating PSMA-Directed Radioligand Therapy in Prostate Cancer Care: Recent Data and Evolving Strategies

Overview:

Prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC), remains a leading cause of cancer-related morbidity and mortality. Although PSMA PET imaging and PSMA-directed radioligand therapy have improved diagnostic and treatment options, clinicians continue to face gaps in knowledge related to patient selection, sequencing, toxicity management, and equitable access to these evolving therapies

This case-based, interactive program is designed to enhance clinician competence and support evidence-based integration of PSMA-directed imaging and radioligand therapy into prostate cancer care.

Learning Objectives:

Upon completion of this activity, participants will be able to:

• Evaluate the role of PSMA PET/CT in diagnosis, staging, and response assessment across the prostate cancer disease continuum.
• Apply evidence-based strategies to integrate and sequence PSMA-directed radioligand therapy in prostate cancer care.
• Implement best practices to manage treatment-related toxicities associated with PSMA-RLT.
• Identify and address barriers to equitable access and delivery of PSMA-targeted therapies in patients with prostate cancer.

Target Audience:

This educational program is directed toward medical oncologists, radiation oncologists, nuclear medicine specialists, APPs, oncology nurses, and other physicians involved in the management of GU cancers.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.